Notable Labs (NASDAQ:NTBL) Shares Down 1.8%

Notable Labs, Ltd. (NASDAQ:NTBLGet Free Report) dropped 1.8% on Tuesday . The stock traded as low as $0.76 and last traded at $0.76. Approximately 31,402 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 319,974 shares. The stock had previously closed at $0.77.

Analyst Ratings Changes

Several equities analysts have recently issued reports on NTBL shares. JMP Securities reissued a “market outperform” rating and set a $9.00 price target on shares of Notable Labs in a report on Monday, April 15th. Chardan Capital cut their price target on Notable Labs from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, May 16th.

View Our Latest Stock Report on Notable Labs

Notable Labs Price Performance

The firm’s fifty day moving average is $0.97 and its two-hundred day moving average is $1.45. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.66 and a quick ratio of 4.66.

Notable Labs (NASDAQ:NTBLGet Free Report) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.42) earnings per share (EPS) for the quarter. On average, analysts anticipate that Notable Labs, Ltd. will post -0.75 EPS for the current fiscal year.

Hedge Funds Weigh In On Notable Labs

An institutional investor recently bought a new position in Notable Labs stock. Industry Ventures L.L.C. purchased a new position in Notable Labs, Ltd. (NASDAQ:NTBLFree Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 204,424 shares of the company’s stock, valued at approximately $386,000. Notable Labs comprises 0.6% of Industry Ventures L.L.C.’s holdings, making the stock its 6th biggest holding. Industry Ventures L.L.C. owned 9.21% of Notable Labs as of its most recent SEC filing. Hedge funds and other institutional investors own 70.48% of the company’s stock.

Notable Labs Company Profile

(Get Free Report)

Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment.

Featured Stories

Receive News & Ratings for Notable Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Notable Labs and related companies with's FREE daily email newsletter.